Viropil
Dolutegravir · Lamivudine · Tenofovir Disoproxil
Indicated to address retroviral duplication to manage HIV disease and alleviate risk of viral progression.
- Category
- HIV Management
- Active ingredients
- Dolutegravir · Lamivudine · Tenofovir Disoproxil
- Route
- Oral use
- Form
- Tablet
- Strengths
- 50mg + 300mg + 300mg
Prescription and consultation requirements for Viropil vary by destination and are determined by the fulfilment partner.
Viropil details
- Alternative names
- dolutegravir, lamivudine, tenofovir
- Therapeutic class
- Integrase Inhibitor, Nucleoside Analog Combination
- Pharmacological class
- Antiretroviral Combination
- Contraindications
- severe renal impairment; concurrent dofetilide use; severe hepatic failure
- Minor side effects
- headache; nausea; insomnia
- Moderate side effects
- diarrhoea; fatigue; elevated cholesterol
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Emcure Pharmaceuticals
- Onset Time
- 2–4 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Antacids; Rifampin; Carbamazepine
- Age restrictions
- Approved for adults weighing over forty kilograms.
Serious side effects
lactic acidosis, requires immediate medical attention; hepatotoxicity, requires immediate medical attention; severe acute hepatitis B flare, requires immediate medical attention
Patient summary
indicated to address retroviral duplication to manage HIV disease and alleviate risk of viral progression.
Mechanism of action
Combines three active agents to block retroviral integration and reverse transcription, halting viral chain growth.
Pregnancy and breastfeeding
TGA Category B/C: Use if benefit outweighs risk. Avoid in early pregnancy. Breastfeeding: Not recommended.